Thread: CNBC had an article today on teevee
I may not have all the quotes word for word,
or the spelling for that matter, but here are
the notes I took:
Carl Seiden-- J.P. Morgan
David Saks-- Gruntal, said this sector outlook is
"best it's ever been"
likes Pfizer, Warner Lambert--for growth
J&J, Merck, Bristol Meyers--for value,
Carl agreed on those three as good ones to own for
their growth, didn't catch what he deemed the value
plays
The phone calls:
re Eli Lily: David said--Prozac under pressure from
competitors solid company, not among the cheapest or fastest
growth
re Bristol Meyers Squibb, --Carl likes it, dependable 14% grower,
"given that it is at 15% discount to the group...a good one to
hold for a couple of years"
Just pick one to own? Carl likes Pfizer, David agreed, pointed
out next years Celebra--and followed it with Warner. Also mentioned
the middlecap in the group as they have been underappreciated.
That was about as much as I could get down--
I usually don't pay any attention to these guys, but the
big drug companies have done so well lately, and my biotechs
have been pummelled so badly lately, I thought, what the heck,
I'll take a few notes and use it as an excuse to ask the thread:
When are these guys going to start buying out some of the
small cap biotech companies?! With their stocks so high, and
the biotechs down so badly, you would think this would be a
good time to do that.
eom |
